Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on August 4, 2016. The report discloses the issuance of a press release regarding financial results for the second quarter ended June 30, 2016. The registrant is incorporated in Delaware and maintains its principal executive offices in Vancouver, B.C., Canada.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced in a press release attached as Exhibit 99.1, which is incorporated by reference but not detailed within the body of this 8-K.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document solely references the announcement of Q2 2016 results without providing comparative data or analysis.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 4, 2016) for actual financial figures and operational updates.
- Verify the company name discrepancy: The request metadata lists "Neurogene Inc.," but the filing is for "Aquinox Pharmaceuticals, Inc."
- Confirm the status of the press release as "furnished" rather than "filed" for legal liability purposes.
- Check subsequent filings for detailed financial statements if the press release lacks granular data.